Drug Trial Radar · NCT05854667
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
440
Planned (sponsor's estimate)
Start
Dec 5, 2023
Primary completion
Dec 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- First posted
- May 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic. The main questions the trial aims to answer are: Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine? Participants will be placed randomly into one of four groups: 1. Usual treatment and placebo 2. Usual treatment, placebo and contingency management 3. Usual treatment and high dose stimulant 4. Usual treatment, high dose stimulant and contingency management Participation includes the following: 1. Participants will receive medication or placebo weekly for 15 weeks. 2. Participants will attend the clinic for weekly treatment 3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.
Conditions
- Methamphetamine Abuse
- Methamphetamine-dependence
- Addiction, Substance
- Addiction
Interventions
Treatment as Usual plus PlaceboDrug
Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
Treatment as Usual plus Placebo plus Contingency ManagementDrug
Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
Treatment as Usual plus lisdexamfetamine (LDX-01)Drug
Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15).
Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency ManagementDrug
Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases: Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of days of methamphetamine use during maintenance phaseTime frame: 12 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Rapid Access Addiction Medicine Clinic, St. Paul's Hospital
Vancouver, British Columbia, Canada · Recruiting
River Stone Recovery Centre
Fredericton, New Brunswick, Canada · Suspended
Center for Addiction and Mental Health
Toronto, Ontario, Canada · Recruiting
University of Montreal Hospital Research Center
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.